GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Heska Corp (NAS:HSKA) » Definitions » Total Stockholders Equity

Heska (HSKA) Total Stockholders Equity : $417.7 Mil (As of Mar. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Heska Total Stockholders Equity?

Heska's Total Stockholders Equity for the quarter that ended in Mar. 2023 was $417.7 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Heska's Book Value per Share for the quarter that ended in Mar. 2023 was $38.26. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Heska's Debt-to-Equity for the quarter that ended in Mar. 2023 was 0.26.

Heska Total Stockholders Equity Historical Data

The historical data trend for Heska's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heska Total Stockholders Equity Chart

Heska Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 122.41 154.36 287.05 435.85 422.21

Heska Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 428.60 417.29 407.90 422.21 417.67

Heska  (NAS:HSKA) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Heska's Book Value per Share for the quarter that ended in Mar. 2023 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(417.671-0)/10.9157
=38.26

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Heska's Debt-to-Equity for the quarter that ended in Mar. 2023 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(4.049 + 105.383) / 417.671
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heska Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Heska's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Heska (HSKA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Heska Corp (NAS:HSKA) » Definitions » Total Stockholders Equity
Comparable Companies
AHCO SILK AVNS UFPT FNA PRCT SIBN CTKB OM TMCI ABT MDT SYK BSX EW SZSE:300760 DXCM ZBH ALGN STE
Traded in Other Exchanges
N/A
Address
3760 Rocky Mountain Avenue, Loveland, CO, USA, 80538
Website
https://www.heska.com
Heska Corp is engaged in developing, manufacturing, marketing, selling, and supporting veterinary products. The company's products include Point of Care diagnostic laboratory instruments and consumables; Point of Care digital imaging diagnostic products; reference laboratory testing; digital cytology services; vaccines; local and cloud-based data services; allergy testing and immunotherapy; single-use offerings such as in-clinic diagnostic tests and heartworm preventive products; and practice information management software and related software. It operates through two segments North America and International. The Company's core strategic focus on Point of Care laboratory and imaging products is included in both segments.
Executives
Joachim A. Hasenmaier director 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Robert L Antin director
Mark F Furlong director 770 M WATER ST, MILWAUKEE WI 53202
Stephen L Davis director 2901 BUTTERFIELD ROAD, OAK BROOK IL 60523
Providenti Anthony C. Jr. officer: EVP, Corporate Development 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Kevin S. Wilson officer: President and COO 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Eleanor F. Baker officer: EVP, Managing Dir. & COO, scil 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Christopher D. Sveen officer: CAO & General Counsel 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Nancy Wisnewski officer: EVP, Prod. Dev. & Cust. Supp 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Sharon L. Riley director 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Catherine Grassman officer: EVP, CFO 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Jason D Aroesty officer: EVP, International Diagnostics 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Bonnie J. Trowbridge director 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Scott Humphrey director 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Jason A Napolitano officer: Exec. VP, CFO & Secretary 1613 PROSPECT PARKWAY, FORT COLLINS CO 80525